ImmunityBio gets Anktiva marketing authorization by European Commission

ImmunityBio (IBRX) announced that the European Commission has granted conditional marketing authorization for Anktiva in combination with Bacillus Calmette-Guerin, or BCG, for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors. As part of the conditional authorization, ImmunityBio will continue to follow up with trial participants and submit long-term safety and efficacy data to the EMA.